We have Answers
We understand that patients may feel overwhelmed by the amount of information available, so we like to keep it simple and answer some of the most frequently asked questions. If you have any additional questions, please complete the contact form on this page.
In addition to performing routine and esoteric oncology-focused testing, we also leverage our research and development expertise to design and validate new assays used for the clinical management of hematologic and urogenital cancers.
What types of products and services does CGI offer?
CGI is an emerging leader in DNA-based cancer diagnostics and services prestigious medical institutions throughout the world. CGI’s tests target cancers that are difficult to diagnose and to predict treatment outcomes which include hematologic, urogenital and HPV-associated cancers.
Products being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI has developed genomic products that are being used in the clinical setting to inform and transform cancer treatment. They include DNA-FISH Probes, CGH Microarrays and Next-Generation Sequencing. CGI also provides services to community hospitals and labs through the Expand Dx™ program and clinical trials services through Select One™.
Why is personalized medicine becoming so important?
Personalized medicine aims to individualize treatments to match each patient with the therapy they are most likely to respond to by assessing their genomic background.
Today only 25% of initial cancer treatments are successful. This is in part due to the traditional approach to treatment selection where one disease is treated similarly in each patient. In addition to the traditional morphologic and pathological analysis, personalized medicine takes into account genomic data and algorithms that can improve success rates in cancer treatment. In addition, genomic assessment requires minimal amount of sampling which is an advantage compared to traditional analysis.
CGI Laboratories complies with the national standard defined by the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) and maintains additional licenses in several states. CGI Laboratories is also accredited by the College of American Pathologists (CAP).
What are CGI’s proprietary products?
CGI has many proprietary products that have launched and that are in the pipeline. Below are brief descriptions of CGI’s proprietary products that have been launched.
- MatBA®-CLL Array-CGH: The Mature B-Cell Neoplasm Array for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (SLL) detects multiple genomic aberrations which are indicative of prognosis of CLL/SLL. For more information, go to MatBA®-CLL/SLL.
- MatBA®-DLBCL Array-CGH: The Mature B-Cell Neoplasm Array for Diffuse Large B-Cell Lymphoma (DLBCL) (MatBA®-DLBCL) assists in patient stratification for risk-adapted therapy when performed at diagnosis. MatBA®-DLBCL assesses the presence of individual prognostic markers as well as genome complexity as measures of overall survival following front-line immunochemotherapy. For more information, go to MatBA®-DLBCL.
- UroGenRA™-Kidney Array-CGH: UroGenRA™-Kidney Array-CGH is specifically designed to classify kidney cancers or renal cell carcinoma (RCC) into three major malignant subtypes and one benign subtype which is critical to patient management and treatment protocols. For more information, go to UroGenRA™-Kidney.
- FHACT™: The FISH-Based HPV-Associated Cancer Test (FHACT™) is the only four color FISH Probe that can be used for cervical cancer screening as additional triage before referral for colposcopy. For more information, go to FHACT™.
What is the MatBA® test?
MatBA®is designed to detect genomic aberrations (gain or loss) found in mature B-cell neoplasms and that present prognostic values. Currently CGI is proposing two applications of the MatBA assay, MatBA®- CLL/SLL and MatBA®-DLBCL, this means that men and women of any age who are diagnosed with CLL, SLL or DLBCL are eligible. Contrary to a whole genome array, MatBA® is a targeted CGH array, this means that only regions with associated clinical value are assessed. In addition, due to the high resolution of the array-CGH methodology, MatBA® can detected genomic aberrations not currently assessed by other methodology (for instance cytogenetics and FISH). To learn more, please visit our site dedicated to MatBA®.
Is MatBA® right for me?
Men and women of any age who are diagnosed with CLL, SLL or DLBCL are eligible. MatBA®-CLL/SLL and MatBA®-DLBCL assays have been both licensed by the states of New Jersey and New-York for routine prognostication in CLL/SLL and DLBCL respectively (see our Accreditations page).
What is the UroGenRA™ test?
UroGenRA™ is a CGH microarray designed to detect genomic aberrations (gain and loss) found in urogenital cancers (kidney, prostate and bladder). The first application of UroGenRA™ is intended to subtype kidney cancer. Clinical management of kidney cancer is directly dependent upon the subtype, and often includes surgical interventions. Despite advancement in imaging techniques, there are still some limitations in distinguishing whether a small renal mass (SRM) is malignant or benign which doesn’t require surgical intervention. In a single test, UroGenRA™-Kidney provides genomic data not available with other tests, for the accurate histologic classification of renal masses. UroGenRA™-Kidney can aid in the subtyping of the main types of kidney cancer, thus reducing the number of unnecessary surgical procedures.
How can FHACT™ aid in cervical cancer screening?
FHACT™ or the FISH-based HPV Associated Cancer Test is a test that uses Fluorescence in situ hybridization to detect the four different genomic aberrations associated with HPV infections and evolution towards pre-cancerous and cancerous lesions.
Over the course of their lives, most women will be exposed to HPV, however 90% of them will clear the infection within two years and only a small fraction of women with HPV will get cervical cancer. Currently, HPV positive women with an abnormal Pap-smear are being referred to biopsy for diagnostication of cervical cancer whereas most of the biopsies will be eventually reported as normal.
By detecting genomic aberrations associated with pre-cancerous and cancerous lesions resulting from HPV infections, FHACT™ can aid in reducing unnecessary procedures.
Will my insurance cover CGI’s clinical work?
CGI is committed to providing patients, clinicians and healthcare professionals with high quality and affordable oncology products and services. CGI understands the insurance process may be challenging for you. Therefore, to make the process easier for you, CGI accepts all private insurances and Medicare. Please contact us at 1 201-528-9230 if you have any questions.
How do I get tested?
The tests offered by CGI are available through your oncologist. Talk to your oncologist about CGI’s clinical services. If you don’t have an oncologist, we can help you find one in your area.